Legend Biotech (LEGN) Tops Q2 EPS by 15c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $255.06 million versus the consensus estimate of $234.23 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• KeyBanc Highlights Murphy Oil Corp. (MUR) Into Earnings
• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Goldman Sachs on Williams Companies (WMB): 'we continue to see strong tailwinds for BTM overall'